artemchuksykitas.blogspot.com
Alvimopan is the active ingredientin Entereg, an Adolo drug that received Food and Drug Administratiohn approval in March as a treatmentr for patients suffering from postoperative ileus, a gastrointestinal disorder, following bowel resection surgery. Adolo (NASDAQ:ADLR), of Exton, Pa., developed Entereg in a partnershipo withGlaxoSmithKline (NYSE:GSK), which earlier this year declined its option to develo p the drug as a treatmenyt for chronic OBD. “Over the past few months, we have conductef an extensive analysis of our OBD saidMichael R. Dougherty, Adolor’s presidenty and CEO.
“While we have made the difficult decisionn to discontinue development of alvimopajin OBD, we remain committed to finding treatments for the millionds of patients suffering from this debilitating condition.” Adolor said the decision was based primarily on the cost of additiona l clinical trials and the limited “commerciakl life” remaining before the company’s patents expir e for alvimopan in OBD. Dougherty said the company is focusinhg its future efforts in chronic OBD on asecondx proprietary, small molecule drug it has in development to treagt the condition.
Adolor is also continuing its developmen of two pain relief products in a partnershi withPfizer (NYSE:PFE).
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment